Get started
Author

Britten K. Gordon

Preclinical evaluation of combination nemtabrutinib and venetoclax in chronic lymphocytic leukemia
2022 · Elizabeth M. Muhowski, Janani Ravikrishnan, et al. · Journal of Hematology & Oncology · 15
PDF
The multi-CDK inhibitor dinaciclib reverses bromo- and extra-terminal domain (BET) inhibitor resistance in acute myeloid leukemia via inhibition of Wnt/β-catenin signaling
2024 · Alexander R. Marr, Madeline Halpin, et al. · Experimental Hematology and Oncology · 13
PDF
Targeting Covalent and Non-Covalent Btki-Resistant CLL Using the Dual Irreversible/Reversible 4 th Generation BTK Inhibitor LP-168
2023 · Britten Gordon, Elizabeth Muhowski, et al. · Blood · 7
PKCβ Inhibitor MS-553 Displays Preclinical Efficacy in Both Treatment-Naïve and BTK Inhibitor–Resistant Chronic Lymphocytic Leukemia
2025 · Britten K. Gordon, Elizabeth M. Muhowski, et al. · Blood Cancer Discovery · 3
T Cell Dysfunction and Exhaustion in Patients with CLL: The Impact of Long Term Ibrutinib Treatment
2023 · Shanmugapriya Thangavadivel, Charlene Mao, et al. · Blood · 3
Targeting Inflammation in Tet2 Mutant Clonal Hematopoiesis Via Inhibition of Brd4 Demonstrates Activity in Both Murine and Human Models
2024 · Alexander R. Marr, Madeline Halpin, et al. · Blood · 2
Genome-Wide CRISPR/Cas9 Knockout Screen Reveals Novel LP-168 (Rocbrutinib) Combinations Targeting BCL-2 Protein Members for Chronic Lymphocytic Leukemia
2024 · Britten K. Gordon, Ethan C. Whipp, et al. · Blood · 2
PDF
The challenge of targeting key drivers of CLL and sequencing therapy in an era of experimental therapeutics
2025 · Britten K. Gordon, Jennifer A. Woyach · Leukemia & lymphoma/Leukemia and lymphoma · 1
Single-Cell RNA-Seq Analysis Reveals Distinct Tumor and Immunosuppressive T Cell Phenotypes in CLL Patients Treated with Ibrutinib
2023 · Shanmugapriya Thangavadivel, Shrilekha Misra, et al. · Blood · 1
The PKC-β Inhibitor MS-553 Displays Preclinical Efficacy in BTK Inhibitor Resistant Chronic Lymphocytic Leukemia
2023 · Britten Gordon, Elizabeth Muhowski, et al. · Blood · 1
PDF
Supplementary Table S4 from Single-Cell RNA-seq Analysis Reveals Distinct Tumor and Immunosuppressive T-Cell Phenotypes in Patients with CLL Treated with Ibrutinib
2026 · Shanmugapriya Thangavadivel, Jami Shaffer, et al.
Supplementary Figure S7 from Single-Cell RNA-seq Analysis Reveals Distinct Tumor and Immunosuppressive T-Cell Phenotypes in Patients with CLL Treated with Ibrutinib
2026 · Shanmugapriya Thangavadivel, Jami Shaffer, et al.
Supplementary Table S3 from Single-Cell RNA-seq Analysis Reveals Distinct Tumor and Immunosuppressive T-Cell Phenotypes in Patients with CLL Treated with Ibrutinib
2026 · Shanmugapriya Thangavadivel, Jami Shaffer, et al.
Supplementary Table S5 from Single-Cell RNA-seq Analysis Reveals Distinct Tumor and Immunosuppressive T-Cell Phenotypes in Patients with CLL Treated with Ibrutinib
2026 · Shanmugapriya Thangavadivel, Jami Shaffer, et al.
Data from Single-Cell RNA-seq Analysis Reveals Distinct Tumor and Immunosuppressive T-Cell Phenotypes in Patients with CLL Treated with Ibrutinib
2026 · Shanmugapriya Thangavadivel, Jami Shaffer, et al.
Supplementary Table S1 from Single-Cell RNA-seq Analysis Reveals Distinct Tumor and Immunosuppressive T-Cell Phenotypes in Patients with CLL Treated with Ibrutinib
2026 · Shanmugapriya Thangavadivel, Jami Shaffer, et al.
Supplementary Figure S3 from Single-Cell RNA-seq Analysis Reveals Distinct Tumor and Immunosuppressive T-Cell Phenotypes in Patients with CLL Treated with Ibrutinib
2026 · Shanmugapriya Thangavadivel, Jami Shaffer, et al.
Supplementary Figure S2 from Single-Cell RNA-seq Analysis Reveals Distinct Tumor and Immunosuppressive T-Cell Phenotypes in Patients with CLL Treated with Ibrutinib
2026 · Shanmugapriya Thangavadivel, Jami Shaffer, et al.
Supplementary Figure S1 from Single-Cell RNA-seq Analysis Reveals Distinct Tumor and Immunosuppressive T-Cell Phenotypes in Patients with CLL Treated with Ibrutinib
2026 · Shanmugapriya Thangavadivel, Jami Shaffer, et al.
Supplementary Figure S4 from Single-Cell RNA-seq Analysis Reveals Distinct Tumor and Immunosuppressive T-Cell Phenotypes in Patients with CLL Treated with Ibrutinib
2026 · Shanmugapriya Thangavadivel, Jami Shaffer, et al.
Supplementary Table S8 from Single-Cell RNA-seq Analysis Reveals Distinct Tumor and Immunosuppressive T-Cell Phenotypes in Patients with CLL Treated with Ibrutinib
2026 · Shanmugapriya Thangavadivel, Jami Shaffer, et al.
Supplementary Table S6 from Single-Cell RNA-seq Analysis Reveals Distinct Tumor and Immunosuppressive T-Cell Phenotypes in Patients with CLL Treated with Ibrutinib
2026 · Shanmugapriya Thangavadivel, Jami Shaffer, et al.
Supplementary Figure S5 from Single-Cell RNA-seq Analysis Reveals Distinct Tumor and Immunosuppressive T-Cell Phenotypes in Patients with CLL Treated with Ibrutinib
2026 · Shanmugapriya Thangavadivel, Jami Shaffer, et al.
Supplementary Table S7 from Single-Cell RNA-seq Analysis Reveals Distinct Tumor and Immunosuppressive T-Cell Phenotypes in Patients with CLL Treated with Ibrutinib
2026 · Shanmugapriya Thangavadivel, Jami Shaffer, et al.
Supplementary Figure S6 from Single-Cell RNA-seq Analysis Reveals Distinct Tumor and Immunosuppressive T-Cell Phenotypes in Patients with CLL Treated with Ibrutinib
2026 · Shanmugapriya Thangavadivel, Jami Shaffer, et al.
Works count: 57
Citation count: 48
H-index: 3
I10-index: 2
Year
Topic
Type